AU770193B2 - Methods of using a somatostatin analogue - Google Patents

Methods of using a somatostatin analogue Download PDF

Info

Publication number
AU770193B2
AU770193B2 AU52447/99A AU5244799A AU770193B2 AU 770193 B2 AU770193 B2 AU 770193B2 AU 52447/99 A AU52447/99 A AU 52447/99A AU 5244799 A AU5244799 A AU 5244799A AU 770193 B2 AU770193 B2 AU 770193B2
Authority
AU
Australia
Prior art keywords
disease
cys
syndrome
pancreatic
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU52447/99A
Other languages
English (en)
Other versions
AU5244799A (en
Inventor
Jacques-Pierre Moreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Publication of AU5244799A publication Critical patent/AU5244799A/en
Application granted granted Critical
Publication of AU770193B2 publication Critical patent/AU770193B2/en
Assigned to IPSEN PHARMA S.A.S reassignment IPSEN PHARMA S.A.S Request to Amend Deed and Register Assignors: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.)
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU52447/99A 1998-07-30 1999-07-29 Methods of using a somatostatin analogue Ceased AU770193B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9469398P 1998-07-30 1998-07-30
US12652598A 1998-07-30 1998-07-30
US60/094693 1998-07-30
US09/126525 1998-07-30
PCT/US1999/017294 WO2000006185A2 (fr) 1998-07-30 1999-07-29 Procedes d'utilisation d'un analogue de somatostatine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004201783A Division AU2004201783A1 (en) 1998-07-30 2004-04-29 Methods of using a somatostatin analogue

Publications (2)

Publication Number Publication Date
AU5244799A AU5244799A (en) 2000-02-21
AU770193B2 true AU770193B2 (en) 2004-02-12

Family

ID=26789150

Family Applications (2)

Application Number Title Priority Date Filing Date
AU52447/99A Ceased AU770193B2 (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue
AU2004201783A Abandoned AU2004201783A1 (en) 1998-07-30 2004-04-29 Methods of using a somatostatin analogue

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2004201783A Abandoned AU2004201783A1 (en) 1998-07-30 2004-04-29 Methods of using a somatostatin analogue

Country Status (16)

Country Link
EP (1) EP1100532A2 (fr)
JP (1) JP2002521456A (fr)
KR (1) KR20010071071A (fr)
CN (1) CN1334742A (fr)
AR (1) AR023633A1 (fr)
AU (2) AU770193B2 (fr)
BR (1) BR9912609A (fr)
CA (1) CA2335654A1 (fr)
CZ (1) CZ2001157A3 (fr)
HU (1) HUP0102839A3 (fr)
IL (2) IL140837A0 (fr)
MX (1) MXPA01000969A (fr)
NO (1) NO324123B1 (fr)
NZ (1) NZ509348A (fr)
PL (1) PL346361A1 (fr)
WO (1) WO2000006185A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040837A3 (fr) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Médicaments pour le traitement des troubles liés à la néovascularisation de lachoroide
AU2001283957A1 (en) * 2000-07-27 2002-02-13 Novartis Ag Treatment of ocular disorders with somatostatin analogues
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
ES2345280T3 (es) 2001-03-06 2010-09-20 The Administrators Of The Tulane Educational Fund Procedimiento de modulacion de la proliferacion de celulas de carcinoma tiroideo medular.
GB0109461D0 (en) * 2001-04-18 2001-06-06 Univ London New Gene
WO2003061592A2 (fr) 2002-01-22 2003-07-31 New York University Methodes de traitement therapeutique de l'hypertrophie benigne de la prostate (bph)
CN107446053A (zh) 2008-06-12 2017-12-08 益普生生物创新有限公司 癌症的抑制
KR101642363B1 (ko) 2008-06-12 2016-07-25 입센 바이오이노베이션 리미티드 신경내분비계 질환의 억제
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN101935252B (zh) * 2010-07-29 2013-01-30 广东省农业科学院科技情报研究所 一种园林植物生长延缓剂及其制备方法
BR112014025058B1 (pt) * 2012-04-12 2022-07-12 Novartis Ag Combinação de análogos de somatostatina com inibidores de 11beta-hidroxilase, e seus usos
CN105168115A (zh) * 2015-09-02 2015-12-23 中国药科大学 生长抑素类似物多肽药物的口服给药途径
WO2017212390A1 (fr) * 2016-06-06 2017-12-14 Emcure Pharmaceuticals Ltd, Procédé de préparation d'acétate de lanréotide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
WO1998008529A1 (fr) * 1996-08-30 1998-03-05 Biomeasure Incorporated Procede d'inhibition de la fibrose a l'aide d'un agoniste de somatostatine
WO1998010786A2 (fr) * 1996-09-12 1998-03-19 Yarom Cohen Composition pharmaceutique pour le traitement du syndrome x de reaven

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
ATE140237T1 (de) * 1989-12-08 1996-07-15 Univ Tulane Oktapeptidanaloge von somatostatin mit threonin in position 6
DE69822810T2 (de) * 1997-05-13 2005-02-03 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
WO1998008529A1 (fr) * 1996-08-30 1998-03-05 Biomeasure Incorporated Procede d'inhibition de la fibrose a l'aide d'un agoniste de somatostatine
WO1998010786A2 (fr) * 1996-09-12 1998-03-19 Yarom Cohen Composition pharmaceutique pour le traitement du syndrome x de reaven

Also Published As

Publication number Publication date
CZ2001157A3 (cs) 2002-02-13
PL346361A1 (en) 2002-02-11
AR023633A1 (es) 2002-09-04
IL181349A0 (en) 2007-07-04
KR20010071071A (ko) 2001-07-28
HUP0102839A2 (hu) 2002-01-28
MXPA01000969A (es) 2003-04-07
NO20010481L (no) 2001-03-21
WO2000006185A2 (fr) 2000-02-10
HUP0102839A3 (en) 2002-02-28
CN1334742A (zh) 2002-02-06
BR9912609A (pt) 2001-05-02
JP2002521456A (ja) 2002-07-16
AU2004201783A1 (en) 2004-05-27
NZ509348A (en) 2004-02-27
IL140837A0 (en) 2002-02-10
WO2000006185A3 (fr) 2000-08-03
NO324123B1 (no) 2007-08-27
AU5244799A (en) 2000-02-21
NO20010481D0 (no) 2001-01-29
EP1100532A2 (fr) 2001-05-23
CA2335654A1 (fr) 2000-02-10

Similar Documents

Publication Publication Date Title
AU770193B2 (en) Methods of using a somatostatin analogue
AU2005318454B2 (en) Sustained release formulation comprising bisphosphonate
US20080242609A1 (en) Composition for the therapy of diabetes mellitus and adiposity
US20130116178A1 (en) Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons
US20070027073A1 (en) Long-acting derivatives of pyy agonists
RU2006107605A (ru) Пептид (варианты), пара аминокислот, снижающие интенсивность по меньшей мере одного симптома воспалительного состояния, фармацевтическая композиция (варианты), лекарственное средство и фармацевтический набор на их основе
US10413594B2 (en) Conjugates of somatostatin analogues
RU98123833A (ru) Способы и композиции, используемые для ингибирования ангиогенеза
EP1228093A2 (fr) Amelioration du transport des peptides par conjugaison avec des acides biliaires
CN101663317A (zh) 胰高血糖素样蛋白-1受体glp-1r激动剂化合物
US6362164B1 (en) Combination of a somatostatin analogue and a rapamycin
WO2010121352A1 (fr) Utilisation de (hexénoyl trans-3)hgrf(1-44)nh2 et de simvastatine dans un traitement combiné
US6150333A (en) Methods of using a somatostatin analogue
O'Donnell et al. Therapeutic potential of a long acting somatostatin analogue in gastrointestinal diseases.
EP1291022A1 (fr) Procédés d'utilisation du lanréotide, un analogue de la somatostatine
EP1648934B1 (fr) Composition pharmaceutique comprenant analogues cycliques de somatostatine
Balaev et al. Synthetic peptide analogs of somatostatin: trends in the synthesis of and prospects in the search for new anticancer drugs
ZA200100793B (en) Methods of using a somatostatin analogue.
EP0657174A1 (fr) Utilisation de la somatostatine
US20100069296A1 (en) Use of somatostatin analogs in cluster headache
JPH04210998A (ja) ペプチド誘導体による消化管の内皮イオン分泌の抑制

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)